Oncogenic Fusions May Be Frequently Present at Resistance of EGFR Tyrosine Kinase Inhibitors in Patients With NSCLC: A Brief Report

Authors:

Abstract
No abstract available
Funding Information
  • Novartis
  • Merck Sharp and Dohme United Kingdom
  • Amgen
  • Roche
  • Astex Pharmaceuticals
  • Bristol-Myers Squibb
  • Sanofi
  • Agios Pharmaceuticals
  • Eli Lilly and Company
  • Spectrum Pharmaceuticals
  • Janssen Pharmaceutica
  • Merck
  • Merck KGaA
  • AstraZeneca (17209098.7)
  • Meso Scale Diagnostics
  • Servier
  • Bayer
  • Boehringer Ingelheim
  • Ipsen
  • Genentech
  • Takeda Pharmaceutical Company
  • Johnson and Johnson
  • GlaxoSmithKline España
  • Celgene
  • Daiichi-Sankyo
  • Astellas Pharma US
  • AbbVie
  • MedImmune
  • Pfizer

This publication has 15 references indexed in Scilit: